CD38-Targeting Isatuximab Combo Active in Refractory Myeloma

Researchers tested the combination of isatuximab with dexamethasone and pomalidomide in patients with relapsed or refractory multiple myeloma.

Source: CancerNetwork - April 9, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news